ReviewInmunologia (Barcelona, Spain : 1987)
Virus-like particle-based vaccines for animal viral infections.
Review in Inmunologia (Barcelona, Spain : 1987). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- Review
- Torque Teno Virus: Lights and Shades.Viruses · 2025Review
- Insect-specific virus platforms for arbovirus vaccine development.Frontiers in immunology · 2025Review
- Article
- Design of Novel Vaccines Based on Virus-Like Particles.Sub-cellular biochemistry · 2024Review
- Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice.PloS one · 2024Article
- Virus-like particles in poultry disease: an approach to effective and safe vaccination.Frontiers in veterinary science · 2024Review
- Virus-Like Particles Based on the Novel Goose Parvovirus (NGPV) VP2 Protein Protect Ducks against NGPV Challenge.Vaccines · 2023Article
- A Virus-like Particle-Based F4 EnterotoxigenicPathogens (Basel, Switzerland) · 2023Article
- Simultaneous Production of a Virus-Like Particle Linked to dsRNA to Enhance dsRNA Delivery for Yellow Head Virus Inhibition.Viruses · 2022Article
- Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.Vaccines · 2022Review
- Article
- Hepatitis B core-based virus-like particles: A platform for vaccine development in plants.Biotechnology reports (Amsterdam, Netherlands) · 2021Review
- Recent Development of Ruminant Vaccine Against Viral Diseases.Frontiers in veterinary science · 2021Review
- Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients.ACS nano · 2020Review
- Molecular Modelling and Insilico Engineering of PapMV-CP Towards Display and Development of Capripox Viral Like Particles Based on Immunogenic P32 Envelop Protein is the Homologous of the Vaccinia-Viral H3L Gene: An Insilico Approach.International journal of peptide research and therapeutics · 2020Article
- The Coming Age of Insect Cells for Manufacturing and Development of Protein Therapeutics.Industrial & engineering chemistry research · 2018Article
- Recent Advances in Vaccine Technologies.The Veterinary clinics of North America. Small animal practice · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination is considered one of the most effective ways to control pathogens and prevent diseases in humans as well as in the veterinary field. Traditional vaccines against animal viral diseases are based on inactivated or attenuated viruses, but new subunit vaccines are gaining attention from researchers in animal vaccinology. Among these, virus-like particles (VLPs) represent one of the most appealing approaches opening up interesting frontiers in animal vaccines. VLPs are robust protein scaffolds exhibiting well-defined geometry and uniformity that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines; nevertheless, only one veterinary VLP-base vaccine is licensed. Here, we review and examine in detail the current status of VLPs as a vaccine strategy in the veterinary field, and discuss the potential advantages and challenges of this technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.